evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1 questions · 1 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review